Key clinical point: Patients with early breast cancer were more likely than were cancer-free peers to develop atrial fibrillation (AF).
Major finding: The rate of AF was elevated in the first year post diagnosis (hazard ratio, 2.16) and after 5 years postdiagnosis (hazard ratio, 1.20), with greater elevation for women who received chemotherapy.
Study details: Population-based retrospective cohort study of 68,113 women diagnosed with early-stage breast cancer and matched 1:3 to cancer-free control women.
Disclosures: Dr. Abdel-Qadir reported receiving grants from the Canadian Cardiovascular Society during the conduct of the study, speaker fees from Amgen, and an honorarium for clinical events adjudication committee membership from the Canadian Vigour Centre for a study funded by AstraZeneca. The study was funded by the Canadian Cardiovascular Society Atrial Fibrillation Research Award.
Abdel-Qadir H et al. JAMA Netw Open. 2019 Sep 4;2(9):e1911838.